Functional Genetic Diversity in the High-Affinity Carnitine Transporter OCTN2 (SLC22A5)
- 1 November 2006
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 70 (5) , 1602-1611
- https://doi.org/10.1124/mol.106.028126
Abstract
Systemic carnitine deficiency (SCD) is a rare autosomal recessive disease resulting from defects in the OCTN2 (SLC22A5) gene, which encodes the high-affinity plasma membrane carnitine transporter. Although OCTN2 is fairly well studied in its relationship with SCD, little is known about the carrier frequency of disease-causing alleles of OCTN2, or of more common functional polymorphisms in this gene. To address these issues, we screened for genetic variants in the OCTN2 coding region by direct sequencing of the exons and flanking intronic region of OCTN2 in a large sample (n = 276) of ethnically diverse subjects. In addition, we established lymphoblastoid cell lines from subjects homozygous for either allele of the previously identified promoter region variant, -207G>C. We found eight amino acid sequence variants of OCTN2, of which three (Phe17Leu, Leu144Phe, and Pro549Ser) were polymorphic in at least one ethnic group. When assayed for functional activity by expression in human embryonic kidney 293 cells, using as probes both the endogenous substrate (l-carnitine) and the organic cation tetraethylammonium, three variants showed functional differences from the reference OCTN2 (Phe17Leu, Tyr449Asp, Val481Phe; p < 0.05). Further studies of the Phe17Leu polymorphism showed a reduced Vmax for l-carnitine transport to approximately 50% of the reference OCTN2. Confocal microscopy studies using an OCTN2-GFP fusion protein showed that Phe17Leu had distinct subcellular localization from the reference OCTN2, with diffuse cytoplasmic retention of Phe17Leu, in contrast to reference OCTN2, which localized specifically to the plasma membrane. Lymphoblasts from subjects homozygous for the -207G allele showed increased l-carnitine transport compared with the -207C/C homozygotes (p < 0.05). This study suggests that although loss-of-function mutations in OCTN2 are likely to be rare, common variants of OCTN2 found in healthy populations may contribute to variation in the disposition of carnitine and some clinically used drugs.This publication has 38 references indexed in Scilit:
- Pharmacological rescue of carnitine transport in primary carnitine deficiencyHuman Mutation, 2006
- Uptake of Cardiovascular Drugs Into the Human HeartCirculation, 2006
- Tyrosine Residues Affecting Sodium Stimulation of Carnitine Transport in the OCTN2 Carnitine/Organic Cation TransporterJournal of Biological Chemistry, 2004
- Functional Regions of Organic Cation/Carnitine Transporter OCTN2 (SLC22A5): Roles in Carnitine RecognitionDrug Metabolism and Pharmacokinetics, 2004
- Functional Domains in the Carnitine Transporter OCTN2, Defective in Primary Carnitine DeficiencyPublished by Elsevier ,2003
- Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Mutations Identified by MS/MS-Based Prospective Screening of Newborns Differ from Those Observed in Patients with Clinical Symptoms: Identification and Characterization of a New, Prevalent Mutation That Results in Mild MCAD Deficiency*American Journal of Human Genetics, 2001
- Genetic Epidemiology of the Carnitine Transporter OCTN2 Gene in a Japanese Population and Phenotypic Characterization in Japanese Pedigrees with Primary Systemic Carnitine DeficiencyHuman Molecular Genetics, 1999
- Primary defect of juvenile visceral steatosis (jvs) mouse with systemic carnitine deficiency is probably in renal carnitine transport systemBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1994
- Carnitine--metabolism and functionsPhysiological Reviews, 1983
- Amino Acid Difference Formula to Help Explain Protein EvolutionScience, 1974